The mutation, overexpression, and amplification of c-Met are often observed in cancers such as gastric cancer and non-small-cell lung cancer (NSCLC) at different stages and even after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [2]. This evidence concerns the gene MET and cancer.